{"groups":[{"description":"Patients receive ixazomib citrate PO on days 1, 8, and 15 and ibrutinib PO daily on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.\\>\n\n\\> Ibrutinib: Given PO\\>\n\n\\> Ixazomib Citrate: Given PO\\>\n\n\\> Laboratory Biomarker Analysis: Correlative studies\\>\n\n\\> Pharmacodynamic Study: Correlative studies\\>\n\n\\> Pharmacokinetic Study: Correlative studies","id":"FG000","title":"Treatment (Ixazomib Citrate, Ibrutinib)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Other"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"21"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"5"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"16"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}